HomeNewsOpinionFDI Policy | India finally bites the Chinese bullet

FDI Policy | India finally bites the Chinese bullet

India’s response is part of a worldwide trend where Chinese predatory trade practices and weaponisation of trade has generated an intense backlash. COVID-19 has just accelerated this process

May 10, 2020 / 18:29 IST
Story continues below Advertisement
Representative Image
Representative Image

On April 18, New Delhi took a significant decision when it amended its extant FDI policy to make prior governmental approval mandatory for foreign investments from countries that share land border with India to curb ‘opportunistic takeovers’ of domestic firms at a time when global coronavirus pandemic is upending the rules of the economic game worldwide.

This amendment to the FDI rule states, “A non-resident entity can invest in India, subject to the FDI policy except in those sectors/activities which are prohibited. However, an entity of a country, which shares a land border with India or where the beneficial owner of investment into India is situated in or is a citizen of any such country, can invest only under the government route.” Along with this, another important shift entailed blocking the indirect acquisition of investments by entities based in China with the change in ownership of the investment also requiring clearance from the Indian government.

Story continues below Advertisement

Beijing’s reaction, predictably, has been strong with the Chinese Embassy in India stating that “the additional barriers set by Indian side for investors from specific countries violate WTO's principle of non-discrimination, and go against the general trend of liberalisation and facilitation of trade and investment” and hoping that “India would revise relevant discriminatory practices, treat investments from different countries equally, and foster an open, fair and equitable business environment.”

The immediate cause for bringing this amendment may have to do with the backlash that the government has been facing since the Peoples Bank of China (PBoC) raised its stake in India's largest non-banking mortgage provider HDFC from 0.8 percent to 1.01 percent. However, there are larger issues behind this decision which are likely to transform the trajectory of India-China ties, especially after the negative externalities generated by the COVID-19 pandemic.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show